Friday, August 3, 2018

Financial Comparison: Invesco (IVZ) versus Morningstar (MORN)

Morningstar (NASDAQ: MORN) and Invesco (NYSE:IVZ) are both business services companies, but which is the better business? We will compare the two businesses based on the strength of their earnings, profitability, dividends, analyst recommendations, risk, valuation and institutional ownership.

Profitability

Get Morningstar alerts:

This table compares Morningstar and Invesco’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Morningstar 16.15% 17.53% 10.28%
Invesco 21.64% 12.70% 3.61%

Analyst Ratings

This is a breakdown of current ratings and recommmendations for Morningstar and Invesco, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Morningstar 0 0 0 0 N/A
Invesco 0 6 7 0 2.54

Invesco has a consensus target price of $36.92, indicating a potential upside of 43.00%. Given Invesco’s higher possible upside, analysts clearly believe Invesco is more favorable than Morningstar.

Dividends

Morningstar pays an annual dividend of $1.00 per share and has a dividend yield of 0.8%. Invesco pays an annual dividend of $1.20 per share and has a dividend yield of 4.6%. Invesco pays out 44.4% of its earnings in the form of a dividend. Morningstar has raised its dividend for 6 consecutive years and Invesco has raised its dividend for 9 consecutive years. Invesco is clearly the better dividend stock, given its higher yield and longer track record of dividend growth.

Valuation & Earnings

This table compares Morningstar and Invesco’s top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Morningstar $911.70 million 6.13 $136.90 million N/A N/A
Invesco $5.16 billion 2.04 $1.13 billion $2.70 9.56

Invesco has higher revenue and earnings than Morningstar.

Risk and Volatility

Morningstar has a beta of 0.79, meaning that its stock price is 21% less volatile than the S&P 500. Comparatively, Invesco has a beta of 1.7, meaning that its stock price is 70% more volatile than the S&P 500.

Insider & Institutional Ownership

38.3% of Morningstar shares are owned by institutional investors. Comparatively, 80.1% of Invesco shares are owned by institutional investors. 57.5% of Morningstar shares are owned by company insiders. Comparatively, 1.8% of Invesco shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Invesco beats Morningstar on 9 of the 15 factors compared between the two stocks.

Morningstar Company Profile

Morningstar, Inc. provides independent investment research services in North America, Europe, Australia, and Asia. It offers a line of data, research, and software tools on a range of investment offerings, including managed investment products, publicly listed companies, fixed income securities, private capital markets, and real-time global market data for financial advisors, asset managers, retirement plan providers and sponsors, and individual and institutional investors. The company offers Morningstar Data, an investment data spanning various investment databases, including pricing and commodity data; Morningstar Direct, an institutional investment research platform; investment management solutions, which include Morningstar Managed Portfolios, the strategist models on third-party managed account platforms, as well as services for institutional asset management, asset allocation, and manager selection; institutional asset management services for asset management firms, broker-dealers, and insurance providers; Morningstar Advisor Workstation, a Web-based investment planning system; and Morningstar.com, a Website for individual investors. It also provides Morningstar Enterprise Components, a set of tools and capabilities that builds customized Websites or enhances existing solutions; Morningstar Research, which includes equity research and manager research; Morningstar Credit Ratings that provides new issue and surveillance ratings and analysis for structured credits, as well as operational risk assessment services; Morningstar Indexes, a set of investment indexes; workplace solutions, such as retirement advice and managed accounts, fiduciary services, and custom models; a mobile application, excel plug-in, data feeds, and data solutions; equity and manager research, and credit rating services; and institutional asset management, asset allocation, and manager selection services. The company was founded in 1984 and is headquartered in Chicago, Illinois.

Invesco Company Profile

Invesco Ltd. is a publicly owned investment manager. The firm provides its services to retail clients, institutional clients, high-net worth clients, public entities, corporations, unions, non-profit organizations, endowments, foundations, pension funds, financial institutions, and sovereign wealth funds. It manages separate client-focused equity and fixed income portfolios. The firm also launches equity, fixed income, commodity, multi-asset, and balanced mutual funds for its clients. It launches equity, fixed income, multi-asset, and balanced exchange-traded funds. The firm also launches and manages private funds. It invests in the public equity and fixed income markets across the globe. The firm also invests in alternative markets, such as commodities and currencies. For the equity portion of its portfolio, it invests in growth and value stocks of large-cap, mid-cap, and small-cap companies. For the fixed income portion of its portfolio, the firm invests in convertibles, government bonds, municipal bonds, treasury securities, and cash. It also invests in short term and intermediate term bonds, investment grade and high yield bonds, taxable and tax-free bonds, senior secured loans, and structured securities such as asset-backed securities, mortgage-backed securities, and commercial mortgage-backed securities. The firm employs absolute return, global macro, and long/short strategies. It employs quantitative analysis to make its investments. The firm was formerly known as Invesco Plc, AMVESCAP plc, Amvesco plc, Invesco PLC, Invesco MIM, and H. Lotery & Co. Ltd. Invesco Ltd. was founded in December 1935 and is based in Atlanta, Georgia with an additional office in Hamilton, Bermuda.

Thursday, August 2, 2018

Best Small Cap Stocks To Own Right Now

tags:AGII,GLMD,INSY,

Small cap Tex Mex or Mexican restaurant stock El Pollo LoCo Holdings Inc (NASDAQ: LOCO) reported�Q2 2017 earnings after the market closed Thursday.

Total revenue increased 8.3% to $105.6 million as system-wide comparable restaurant sales increased 2.9% -�including a 2.4% increase for company-operated restaurants and a 3.2% increase for franchised restaurants. The growth in company-operated restaurant revenue was largely driven by the 24 new restaurants opened during and subsequent to the second quarter of 2016. Comparable company-operated restaurant sales increased 2.4%, driven by a 0.5% increase in transactions and a 1.9% increase in average check. Net income was $7.8 million versus net income of $7.3 million. The CEO commented:

"During the second quarter we achieved solid results, including system-wide comparable store sales growth of 2.9% and a return to positive transaction growth.� Our core business continues to perform well, driven by our strategy to highlight our authentic brand, our differentiated offerings, and our QSR+ positioning.� Additionally we made progress against new technology initiatives focused on driving convenience and loyalty, rolling out delivery and launching our all-new Loco Rewards loyalty program."

Best Small Cap Stocks To Own Right Now: Argo Group International Holdings Ltd.(AGII)

Advisors' Opinion:
  • [By Stephan Byrd]

    Argo Group (NASDAQ: AGII) and Stewart Information Services (NYSE:STC) are both small-cap finance companies, but which is the better business? We will compare the two companies based on the strength of their valuation, risk, earnings, dividends, institutional ownership, profitability and analyst recommendations.

  • [By Max Byerly]

    Lord Abbett & CO. LLC purchased a new position in shares of Argo Group (NASDAQ:AGII) in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund purchased 840,251 shares of the insurance provider’s stock, valued at approximately $48,230,000. Lord Abbett & CO. LLC owned approximately 2.49% of Argo Group as of its most recent filing with the SEC.

  • [By Joseph Griffin]

    Barclays PLC raised its stake in Argo Group (NASDAQ:AGII) by 25.3% during the first quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 8,691 shares of the insurance provider’s stock after acquiring an additional 1,754 shares during the period. Barclays PLC’s holdings in Argo Group were worth $499,000 as of its most recent SEC filing.

Best Small Cap Stocks To Own Right Now: Galmed Pharmaceuticals Ltd.(GLMD)

Advisors' Opinion:
  • [By Jon C. Ogg]

    Galmed Pharmaceuticals Ltd. (NASDAQ: GLMD) was started as Outperform with a $26 price target at Raymond James on July 20, and that was versus a previous $15.02 closing price. A week earlier, on�June 13, Stifel Nicolaus initiated Galmed with a Buy rating and issued a $35 price target that would imply more than 100% upside. Galmed has been quite volatile as its 52-week range is listed at $3.61 to $27.06. It had a $322 million market cap as of�Friday. Galmed, which focuses on diseases and issues targeting the liver, closed at $15.00�on Friday. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria.

  • [By Keith Speights]

    That's exactly what happened this week with three small biotech stocks. Galmed Pharmaceuticals (NASDAQ:GLMD), Galectin Therapeutics (NASDAQ:GALT), and Eloxx Pharmaceuticals (NASDAQ:ELOX) soared on news that excited investors. Here's what drove these stocks higher -- and whether or not they're smart picks for investors now.

  • [By George Budwell]

    Over the last two weeks, shares of�Madrigal Pharmaceuticals (NASDAQ:MDGL), Galmed Pharmaceuticals (NASDAQ:GLMD), and Viking Therapeutics (NASDAQ:VKTX) have more than doubled in value. The reason?

  • [By Shane Hupp]

    Here are some of the media stories that may have effected Accern’s rankings:

    Get Galmed Pharmaceuticals alerts: Galmed Pharmaceuticals’ (GLMD) CEO Allen Baharaff on Q1 2018 Results – Earnings Call Transcript (seekingalpha.com) What You Must Know About Galmed Pharmaceuticals Ltd��s (NASDAQ:GLMD) Market Risks (finance.yahoo.com) Obeticholic Acid Market Analysis, Recent Trends and Regional Growth Forecast by Types, Applications and Economic … (theexpertconsulting.com) oholic Steatohepatitis (NASH) Market 2023: Know Marketing Channel Future Trend, Growth and Price with Future … (theexpertconsulting.com) Umbilical Cord Blood May Offer Early FH Diagnosis (medscape.com)

    A number of equities analysts have recently commented on GLMD shares. ValuEngine lowered shares of Galmed Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, February 14th. Maxim Group set a $14.00 price target on shares of Galmed Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, May 9th. Finally, HC Wainwright lifted their price target on shares of Galmed Pharmaceuticals from $18.00 to $24.00 and gave the stock a “buy” rating in a report on Monday, February 12th. Two research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and an average price target of $20.40.

  • [By Sean Williams]

    Similar strength was seen from microcap Galmed Pharmaceuticals (NASDAQ:GLMD), which rose by more than 150% during a single trading session two weeks ago despite mixed results. The move followed the release of phase 2b data from its 52-week Arrest study for NASH drug hopeful Aramchol. In that trial, a statistically significant reduction in liver fat was noted with one of the two doses (the 400 mg dose). However, the 600 mg dose led to a statistically significant improvement in overall NASH resolution (19.2% vs. 7.5%) and NASH resolution without worsening of fibrosis (16.7% vs. 5%) relative to the placebo.�

  • [By George Budwell]

    Shares of the clinical-stage biotech Galmed Pharmaceuticals (NASDAQ:GLMD) are on absolute fire this morning, thanks to a positive midstage trial readout for its experimental nonalcoholic steatohepatitis (NASH) drug Aramchol. Specifically, the company reported that patients receiving the 400 mg dose of Aramchol exhibited a significant reduction in liver fat over the study period compared to those taking a placebo. Curiously, though, patients receiving the higher dose of 600 mg apparently only showed a statistically significant drop in liver fat relative to placebo patients in a post-hoc analysis, according to the press release.�

Best Small Cap Stocks To Own Right Now: Insys Therapeutics, Inc.(INSY)

Advisors' Opinion:
  • [By Keith Speights]

    The Intelligent Investor was written in 1949, but it's still as relevant nearly 70 years later as it was back then. Benjamin Graham was right about how crazy the market can be at times. I think the experiences of two very different biotech stocks this week -- Celgene (NASDAQ:CELG) and Insys Therapeutics (NASDAQ:INSY)�-- prove the point.

  • [By Max Byerly]

    Get a free copy of the Zacks research report on Insys Therapeutics (INSY)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Keith Speights]

    What about�Insys Pharmaceuticals (NASDAQ:INSY)? The biotech's lead product is an opioid drug, but it also has an approved cannabinoid drug on the market for treating�anorexia in people with AIDS who have lost weight, and chemotherapy-induced nausea and vomiting. Insys�has a couple of experimental pain drugs in its pipeline -- but none of them are cannabinoids. The company's lead cannabinoid candidate targets childhood absence epilepsy, infantile spasms, genetic disorder Prader-Willi syndrome -- but not pain.

  • [By Casey Wilson]

    Others, like cannabis biotech firm Insys Therapeutics Inc. (Nasdaq: INSY), are direct plays in marijuana businesses that offer investors the opportunity for incredibly fast gains.

  • [By Keith Speights]

    Insys Pharmaceuticals (NASDAQ:INSY) and Cara Therapeutics (NASDAQ:CARA) fall into the third category. However, the designations of both Insys and Cara as marijuana�stocks warrant an asterisk. Insys' cannabinoid drug Syndros is based on a synthetic form of THC, the primary psychoactive chemical in marijuana. Cara has a cannabinoid receptor agonist, CR701, in preclinical development.

Wednesday, August 1, 2018

TripAdvisor (TRIP) Stock Plummeted on Q2 Revenue Miss

TripAdvisor (NASDAQ:TRIP) reported its latest quarterly earnings results on Monday, which were mixed as the company’s earnings was ahead of expectations, while its revenue was below analysts’ outlook, sending shares sinking late in the day.

TripAdvisor (TRIP)The Massachusetts-based travel and restaurant website said that for its second quarter of fiscal 2018, it brought in a profit of 23 cents per share. On an adjusted basis when considering one-time gains and costs, the company earned 41 cents per share.

TripAdvisor’s earnings were better than the average estimate of the Zacks Investment Research, which amassed information through a survey of 14 analysts, of 39 cents per share. On the revenue front, the company raked in sales of $433 million, which was below the $436.1 million that the Wall Street consensus estimate called for, according to the Zacks poll.

Total revenue was up by 2% compared to the year-ago quarter thanks to the company’s positive results for its non-hotel revenue. TripAdvisor’s adjusted EBITDA marked an increase of 8% compared to the year-ago period.

The company’s Experiences category of non-hotel revenue was its strongest metric as the platform experienced a nearly two-fold increase in the number of bookable experiences to 121,000, ahead of the 61,000 from TripAdvisor’s second quarter of fiscal 2017.

TRIP stock fell about 0.6% during regular trading hours in anticipation of the company’s quarterly earnings report, which sent shares plummeting nearly 12.1% after the bell on its revenue miss.

Compare Brokers